 ROCKVILLE, Md., July 1, 2021 PRNewswire -- RegeneRx Biopharmaceuticals, Inc. OTCQB: RGRX RegeneRx, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it closed its previously announced private placement offering of common stock and warrants for gross proceeds of 1,980,000. 